CorriXR Therapeutics, Inc.

CorriXR Therapeutics is a biotechnology company focused on oncology, specializing in the development of targeted genetic medicines using CRISPR-based gene editing technology. The company was spun out of the ChristianaCare Gene Editing Institute and maintains a close collaborative relationship with its researchers and the Helen F. Graham Cancer Center & Research Institute. Its lead program, CXR101, is a genetic therapy designed to disable NRF2, a transcription factor often hyperactive in squamous cell cancers, including lung, head and neck, and esophageal squamous cell carcinomas. By utilizing localized delivery via ionizable lipid nanoparticles, the platform aims to precisely target tumor cells while sparing healthy tissue and limiting systemic toxicity, thereby addressing the survival mechanisms of treatment-resistant tumors.

The company’s approach is designed to improve patient outcomes by overcoming common challenges associated with traditional chemotherapy and radiation, such as diminished quality of life and drug resistance. By targeting the biology that sustains tumor growth rather than just the initial oncogenic mutations, CorriXR seeks to provide more effective therapeutic options for patients battling aggressive, treatment-resistant cancers. The organization, founded in 2022 and headquartered in Newark, Delaware, leverages an expert-driven model that integrates translational science with clinical oncology to advance its pipeline from preclinical research toward future therapeutic applications.